Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Operating Leases (2023 - 2025)

Historic Operating Leases for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $134.0 million.

  • Genmab A's Operating Leases rose 229.01% to $134.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $134.0 million, marking a year-over-year increase of 229.01%. This contributed to the annual value of $134.0 million for FY2025, which is 229.01% up from last year.
  • Genmab A's Operating Leases amounted to $134.0 million in Q4 2025, which was up 229.01% from $143.0 million recorded in Q1 2025.
  • Genmab A's Operating Leases' 5-year high stood at $143.0 million during Q1 2025, with a 5-year trough of $101.0 million in Q4 2023.
  • For the 3-year period, Genmab A's Operating Leases averaged around $127.2 million, with its median value being $132.5 million (2024).
  • As far as peak fluctuations go, Genmab A's Operating Leases soared by 2970.3% in 2024, and later soared by 229.01% in 2025.
  • Genmab A's Operating Leases (Quarter) stood at $101.0 million in 2023, then grew by 29.7% to $131.0 million in 2024, then increased by 2.29% to $134.0 million in 2025.
  • Its Operating Leases was $134.0 million in Q4 2025, compared to $143.0 million in Q1 2025 and $131.0 million in Q4 2024.